Keeping it hot: Radiofrequency ablation of atrial fibrillation in a patient with cold agglutinin disease Authors: Daniel D. Moylan, Eitan Frankel, Douglas S. Pfeil, Daniel R. Frisch Published: 2026 Key Teaching Points •Atrial fibrillation ablation for patients with cold agglutinin disease can be performed effectively using warmed saline (41°C) through a radiofrequency (RF) ablation catheter.•RF may be preferred over other modalities such as cryoablation or pulsed field ablation because of a lower risk of hemolysis with RF ablation.•Multidisciplinary procedural preparation including preprocedural complement inhibition with sutimlimab and strict temperature optimization is crucial for hemolysis prevention. Key Teaching Points •Atrial fibrillation ablation for patients with cold agglutinin disease can be performed effectively using warmed saline (41°C) through a radiofrequency (RF) ablation catheter.•RF may be preferred over other modalities such as cryoablation or pulsed field ablation because of a lower risk of hemolysis with RF ablation.•Multidisciplinary procedural preparation including preprocedural complement inhibition with sutimlimab and strict temperature optimization is crucial for hemolysis prevention. •Atrial fibrillation ablation for patients with cold agglutinin disease can be performed effectively using warmed saline (41°C) through a radiofrequency (RF) ablation catheter. Atrial fibrillation ablation for patients with cold agglutinin disease can be performed effectively using warmed saline (41°C) through a radiofrequency (RF) ablation catheter. •RF may be preferred over other modalities such as cryoablation or pulsed field ablation because of a lower risk of hemolysis with RF ablation. RF may be preferred over other modalities such as cryoablation or pulsed field ablation because of a lower risk of hemolysis with RF ablation. •Multidisciplinary procedural preparation including preprocedural complement inhibition with sutimlimab and strict temperature optimization is crucial for hemolysis prevention. Multidisciplinary procedural preparation including preprocedural complement inhibition with sutimlimab and strict temperature optimization is crucial for hemolysis prevention. Introduction Cold agglutinin disease (CAgD) is a condition in which low temperatures cause cold agglutinin autoantibodies to agglutinate erythrocytes, subsequently activating complement-mediated autoimmune hemolytic anemia. The disease accounts for approximately 15% of all autoimmune hemolytic anemias and causes cold-induced circulatory symptoms such as acrocyanosis and ischemia in addition to hemolysis.1,2 CAgD creates significant challenges in procedural environments because it requires strict temperature control to avoid hemolysis, and surgery is a known cause of exacerbations.3 In addition, induction of general anesthesia, which is often required for these procedures, can lead to the lowering of core body temperatures through redistribution. Although periprocedural management strategies for CAgD, including perioperative plasma exchange, warmed products, body-warming blankets, and intraoperative core body temperature monitoring, have been described in isolated cases, there are no consensus recommendations for procedural management. With regard to atrial fibrillation (AF), the periprocedural management, efficacy, and safety of ablation of AF in patients with CAgD have not been previously described. Furthermore, there is a paucity of evidence in the literature describing the disease course of AF in CAgD. Case report A 70-year-old woman with symptomatic paroxysmal AF and CAgD presented to the electrophysiology clinic for rhythm control management of AF. The patient was originally diagnosed as having CAgD approximately 10 years before the visit after an acute case of anemia with illness and years of infrequent cyanosis of the fingers and toes when exposed to cold weather. Approximately 5 years before presentation, the patient was hospitalized with pneumonia that exacerbated her CAgD and caused her hemoglobin to decline to 6.6 g/dL from a baseline of approximately 10 g/dL. At that time, she was first diagnosed as having AF. For her CAgD, she received 4 doses of rituximab (anti-CD20 monoclonal antibody) with hemoglobin stabilization at approximately 10 g/dL. She was also treated with aspirin 81 mg for the reduction of venous thromboembolism risk. After the initiation of treatment, the patient experienced an indolent period of disease with occasional exacerbations of anemia triggered by cold weather and infections with symptoms including dark urine, severe fatigue, and acrocyanosis. At her initial presentation to the electrophysiology clinic, the patient reported intermittent episodes of AF with palpitations lasting up to 1 hour. In addition to infrequent infections and dehydration, her AF seemed to be primarily driven by episodes of anemia with exacerbations of her CAgD. For rate control and symptom reduction, the patient was managed with diltiazem 30 mg by mouth every 4 hours as needed, which was reported to be effective. She had previously declined anticoagulation. The initial rhythm control strategy was monitoring for AF with her smart watch and mobile electrocardiogram device with consideration of anticoagulation, antiarrhythmic therapy, and ablation if the patient experienced frequent or lengthy (approximately 24 hours) episodes of AF. At a 12-month follow-up visit, the patient reported increasing frequency of episodes of both anemia and symptomatic AF despite daily diltiazem use. These episodes had prompted several emergency department visits where she was treated with intravenous (IV) fluids and additional diltiazem. Given the increasing frequency of her symptomatic paroxysmal AF, we elected to proceed with ablation after multidisciplinary planning with consultations from the anesthesiology and hematology services. For the treatment of her CAgD with persistent anemia, the patient was initiated on sutimlimab, a C1 complement inhibitor, to block complement-mediated hemolysis. The use of plasmapheresis to remove cold agglutinins and thereby prevent agglutination was also considered, but was ultimately decided against because it was unnecessarily invasive and the addition of sutimlimab was felt to be sufficient to maintain the patient’s hemoglobin levels safely throughout the procedure. In addition, a procedural protocol to manage the patient’s CAgD preoperatively (as later detailed in the ablation description) was planned and reviewed with the multidisciplinary team. After the initiation of sutimlimab, the patient’s preoperative testing revealed a hemoglobin level of 11.3 g/dL. On the day of the ablation procedure, the electrophysiology procedure room was warmed to 26°C. A forced air warmer was placed on the patient in the holding area before the induction of anesthesia. Upon entering the procedure room, standard American Society of Anesthesiologists monitors were placed (blood pressure, electrocardiogram, and pulse oximetry). The forced air warmer was attached to a full underbody warmer. The anesthesiology team then induced general anesthesia with endotracheal intubation, and an esophageal probe was placed for temperature monitoring. The patient was then prepped and draped in our usual sterile fashion. Most IV fluids administered by the anesthesiology team were warmed to 41°C using dedicated fluid warmers. 1 medication bolus line was left at room temperature. Radiofrequency energy was selected given concerns for hemolysis with cryotherapy and pulsed field ablation. Ablation was performed using an irrigated catheter with a flow rate of 13 mL/min. Power was set at 50 W with a temperature cutoff of 42°C. Target lesion duration was 8–15 seconds, and goal contact force was 10–20 g. Saline warmed to 41°C was run through the irrigated ablation catheter without any automatic termination of energy delivery owing to high catheter tip temperatures. The pulmonary veins were successfully isolated. After ablation, no tachyarrhythmias were inducible with burst pacing. There was no evidence of hemolysis, and the core temperature remained near 37.9°C (Figure 1). The patient tolerated the procedure with no complications or adverse effects and left the laboratory in stable condition.Figure 1Patient body temperature and average temperature at ablation catheter tip. RF = radiofrequency. Patient body temperature and average temperature at ablation catheter tip. RF = radiofrequency. The patient was discharged on apixaban 5 mg by mouth twice daily. She was advised to hold her daily diltiazem and only take 30 mg 4 times daily by mouth as needed for episodes of AF. At her 2-week follow-up visit, the patient was noted to be doing well overall. She had 2 brief (<1-hour) episodes of AF in the days after her procedure in the setting of severe constipation that resolved. The patient had also experienced a fall, but had no significant trauma on evaluation. Owing to the patient’s preference to stop anticoagulation as soon as safely possible to avoid bleeding risks, the patient’s anticoagulation was discontinued at 8 weeks after her ablation. She returned to the office 4 and a half months after her ablation. At that visit, she reported feeling well with no further instances of palpitations or AF. Discussion There is little consensus regarding procedural optimization for CAgD and minimal evidence regarding the management of AF in this patient population. Commonly used periprocedural strategies for CAgD have included body-warming blankets, warmed IV fluids, strict temperature monitoring, and perioperative plasma exchange.3 1 case series described 6 patients with CAgD who underwent cardiac surgery requiring cardiopulmonary bypass without major adverse morbidity or mortality and identified only 1 episode of postoperative hemolysis.4 Management approaches included preoperative hematology consultation, maintenance of temperature to 37°C, warmed products, and forced air warming devices. Preoperatively, 1 patient underwent plasma exchange and another underwent red blood cell transfusion. Individual case reports have highlighted similar strategies and also offered unique management options for patients with CAgD. In a report of a laparoscopic cholecystectomy, the operating room was warmed to 23°C and IV fluids were warmed to 41°C with a core body temperature goal of approximately 37°C, although 1 IV line clotted and the transfusion of 1 unit of warmed packed red blood cells was required for a hemoglobin decline from 8.5 to 6.4 g/dL.5 Southern et al6 report a case of a patient successfully undergoing radical cystectomy using similar strategies in addition to preoperative plasmapheresis. In addition to a warmed operating room (26°C), forced air warmers (37°C and 40°C), and warmed fluids (40°C) to target a body temperature of 37°C, Koyama et al7 report a lumbar laminectomy in which preoperative amino acid infusion warmed to 41°C was administered to target core temperature to good effect with no clinical evidence of hemolysis. Finally, the addition of prophylactic eculizumab (C5 complement inhibitor) was reported to successfully prevent additional transfusion needs during an aortic valve replacement.8 More recently, sutimlimab, a C1 complement inhibitor with a more proximal inhibition of the complement cascade, has been demonstrated to be effective in preventing hemolysis for patients with CAgD undergoing coronary artery bypass grafting and arch replacement for type A aortic dissection with the use of mild hypothermic circulatory arrest and cold cardioplegia.9,10 Literature regarding the management of AF in patients with CAgD is extremely limited. To the authors’ knowledge, no evidence to date describes the progression of disease or procedural optimization for patients with AF and CAgD. Kumanomido et al11 report a case in which a patient underwent cryoballoon ablation and experienced hyperkalemia resulting in a wide QRS and requiring hemodialysis in a patient retrospectively suspected to have CAgD aggravated by cryoablation. In a patient with known cold hemolytic anemia and cold agglutinins demonstrated at room temperature of 22°C undergoing premature ventricular contraction ablation without special precautions, the patient experienced coronary artery thrombosis leading to significant myocardial ischemia and cardiovascular collapse after the administration of room temperature contrast dye.12 These cases highlight the risk of catheter-directed procedures in this patient population, particularly when special precautions are not taken. This novel case report is the first to describe the progression and management of AF in a patient with CAgD. Notably, the patient’s AF seemed to be primarily driven by her CAgD. Both her initial diagnosed episode and paroxysmal events coincided with exacerbations of CAgD with anemia. As the frequency of her episodes increased alongside increased episodes of anemia despite management of her CAgD and increased age, it is difficult to determine whether the progression of her AF may have also represented degenerative atrial disease. Further research is needed to determine how the progression and severity of AF may differ in patients with CAgD. To the authors’ knowledge, ablation for AF in a patient with CAgD has not been previously described. In this case, generalized temperature management strategies similar to previous reports seemed to be effective. Strict temperature monitoring was used with pre- and intraoperative forced air warmers, room warming to 26°C, and most IV fluids warmed to 41°C. Preinduction forced air warming in the holding area also played an important role, mitigating the reduction of core body temperature via redistribution that is seen on induction of anesthesia.13 Redistribution can reduce core temperatures anywhere from 0.5°C to 1.5°C. In this case, the patient’s core temperature was 36.9°C immediately after induction of anesthesia and did not fall. This strict temperature management, combined with the sutimlimab started in the weeks before her procedure, was effective at preventing hemolysis during the procedure. Uniquely, radiofrequency ablation using saline warmed to 41°C through an irrigated ablation catheter allowed for successful pulmonary vein isolation without termination of energy delivery owing to high tip temperatures. There seemed to be no consequences to irrigating the ablation catheter with warmed saline. The patient’s core temperature remained between 37°C and 38°C, and she did not experience any evidence of hemolysis periprocedurally. Notably, after 2 brief episodes of AF in the first week after the procedure, the patient had no further documented episodes of AF. Thus, this original case demonstrates that, through the use of strict procedural precautions and complement inhibition, radiofrequency ablation for AF can be performed safely and efficaciously in patients with CAgD. Furthermore, it adds to a newly developing body of literature that suggests that the use of sutimlimab may be effective in preventing procedurally triggered hemolysis in patients with CAgD. Conclusion Although the impact of CAgD on the disease course of AF is currently unknown, exacerbations of CAgD resulting in anemia seem to be significant triggers for episodes of AF. Multidisciplinary planning with electrophysiology, anesthesia, and hematology can allow for procedural optimization with strict temperature control and complement inhibiting medications (sutimlimab) to prevent hemolysis. Warmed saline delivered through an irrigated radiofrequency catheter was safe and effective for AF ablation. In the future, proceduralists may consider the methods described to optimize safety for catheter-directed interventions in patients likewise requiring strict temperature management. Funding Sources This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Disclosures The authors have no conflicts of interest to disclose.